Month: April 2021

– Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model – – Preclinical findings support increase of PPi levels as a predictive marker of therapeutic benefit – BOSTON, April 29, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the online pre-publication release of preclinical data suggesting the potential of its lead development candidate, INZ-701, as a treatment for ENPP1 Deficiency. As reported in the Journal of Bone and Mineral Research (JBMR), in an article titled, “INZ‐701 prevents ectopic tissue calcification and restores bone...

HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted for poster presentations during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Salarius submitted three abstracts detailing research regarding seclidemstat, all of which have been accepted for poster presentations, with one abstract also selected for a poster discussion session. ASCO will be held virtually from June 4-8, 2021. The titles of the abstracts are currently available on ASCO’s 2021 Meeting Library with full abstracts, including the dates and times of presentations, scheduled for publication at 5 p.m. ET on May...

Strong Sales and Earnings despite challenging supply chain environment LISLE, Ill., April 29, 2021 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS) today announced first quarter 2021 results.Sales were $128.4 million, up 25% year-over-year. Sales to transportation customers increased 23%, and sales to other end markets grew 27%. The Sensor Scientific acquisition added $1.8 million of sales in the first quarter of 2021. Net earnings were $12.0 million or $0.37 per diluted share versus $3.8 million or $0.12 per diluted share in the first quarter of last year. Adjusted diluted EPS was $0.46, up from $0.19 in the first quarter of 2020. Free cash flow was $18.5 million, up from $7.4 million in the first quarter of 2020. New business wins were $156 million.“We achieved strong results in the quarter supported by robust customer demand....

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE:ACRG.A.U, ACRG.B.U), (OTCQX: ACRHF, ACRDF) a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S., today announced Katrina Yolen has been appointed as the Company’s Chief Marketing Officer effective April 28th. “I am thrilled to welcome Katrina to the Acreage team and look forward to her significantly building brand awareness for our portfolio of brands,” said Peter Caldini, Chief Executive Officer of Acreage. “Katrina’s unique background, which combines traditional CPG brand management and cannabis, is exactly what Acreage needs to further expand its marketing and commercialization capabilities at the local, state, and national levels.” Katrina brings a wealth of marketing and brand management...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials. Details of XLRP Presentation: Session Title: Six-Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis...

– Toripalimab data will also be featured in ASCO’s official press program – SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021. The abstract has also been selected for ASCO’s official press program. Details regarding the plenary session and abstract publication are as follows:Title: JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as...

Coalition Expands Reach and Impact into the Business Community CANTON, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (OTCQX: “DXLG”), the leading omni-channel specialty retailer of Big + Tall men’s clothing and shoes, announced today that it joins the growing coalition pledging to advance diversity and inclusion in the workplace. One of nearly 2,000 CEOs that have come together for CEO Action for Diversity & Inclusion™, Harvey Kanter is committing himself and Destination XL Group, Inc. to this effort. By signing on to this commitment, Destination XL Group, Inc. is pledging to take action to cultivate a workplace where diverse perspectives and experiences are welcomed and respected, and where employees feel encouraged to discuss diversity and inclusion. The collective of nearly 2,000 signatories has already...

– Toripalimab data will also be featured in ASCO’s official press program – SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021. The abstract has also been selected for ASCO’s official press program. Details regarding the plenary session and abstract publication are as follows:Title: JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as...